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There is evidence that raccoon polyomavirus is causative for neuroglial brain tumors in the western
United States. It is unknown if infection is limited to geographic locales where tumors have been
reported or is widespread, like human polyomaviruses. We demonstrate raccoons in western, eastern
and midwestern states have been exposed to RacPyV by detection of antibodies to capsid protein, VP1.
While raccoons in eastern and midwestern states are seropositive, exposure is lower than in the western
states. Additionally, across geographic areas seropositivity is higher in older as compared to younger
raccoons, similar to polyomavirus exposure in humans. Serum titers are signiﬁcantly higher in raccoons
with tumors compared to raccoons without. Unlike polyomavirus-associated diseases in humans, we did
not detect signiﬁcant sequence variation between tumor and non-tumor tissue in raccoons with tumors
compared to those without tumors. This warrants further investigation into co-morbid diseases or
genetic susceptibility studies of the host.
& 2015 Elsevier Inc. All rights reserved.Introduction
Raccoon polyomavirus (RacPyV) was discovered in 2010 in a
cluster of free-ranging raccoons with morphologically similar
neuroglial tumors affecting their olfactory tract and frontal lobe
(Dela Cruz et al., 2013). Every tumor (n¼20) diagnosed to date has
high quantities of RacPyV genomic DNA present as detected by
real-time quantitative polymerase chain reaction (qPCR) (unpub-
lished data). Despite extensive surveillance of raccoons (given
their role as vectors of rabies) and communications with pathol-
ogists and wildlife rehabilitators regarding our research, tumor
cases have only been found in the western United States (Cali-
fornia, Oregon, and Washington). A crucial step in establishing
whether RacPyV plays a causal role in these tumors is to deter-
mine if exposure to RacPyV is limited to locations where
tumors occur.
As measured by seroprevalence studies, exposure to human
polyomaviruses (PyVs) is widespread and, in general, PyVs cause
lifelong, clinically silent infections (DeCaprio and Garcea, 2013).
However, polyomaviral-associated disease does occur-mainly inen C. Drayer Wildlife Health
alifornia, Davis, 2015.
ward, National Institutes of
raining Program, 2012–2015.severely immune suppressed people following long term, persis-
tent infection (Moore and Chang, 2010). The majority of adult
humans have antibodies to all 13 identiﬁed human poly-
omaviruses (DeCaprio and Garcea, 2013; Nicol et al., 2013; Ehlers
and Wieland, 2013; Mishra et al., 2014). Very little has been
published regarding seroprevalence of naturally occurring poly-
omaviruses in animals, though one long-term study demonstrated
high seroprevalence of avian polyomavirus in psittacines (Deb
et al., 2010). We hypothesize that exposure to RacPyV mirrors that
of human polyomavirus, with geographically widespread ser-
oprevalence not restricted to areas where tumors have been
identiﬁed. Moreover, we postulate that while exposure is wide-
spread, associated disease is rare. To examine the geographic
distribution of RacPyV seroprevalence and correlate it to disease
status, we compared seropositivity in raccoons sampled from 11
states within the U.S. and three Canadian provinces. We evaluated
seropositivity and serological titers with respect to geography,
disease status, age, sex, and habitat.
Sequence variation between polyomavirus genotypes has been
demonstrated to have effects on pathological outcomes (Sunyaev
et al., 2009; Ferenczy et al., 2012; Carroll et al., 2007). For example,
sequences in the noncoding region of the polyomavirus genome
differ between tumor tissue and non-tumor tissues (sites of viral
persistence) in mouse polyomavirus (Talmage et al., 1992) and
Merkel cell polyomavirus (Segondy and Foulongne, 2009), PyVs
which infect mice and humans, respectively. In addition, single
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ing in single amino acid differences, have been associated with
tumorigenic and nonpathogenic strains of mouse polyomavirus
(Carroll et al., 2007). Comparing RacPyV isolates from different
geographic locales, as well as isolates from tumor or non-tumor
tissues could reveal speciﬁc sequence variations associated with
tumor formation.Results
Seroprevalence of RacPyV
A total of 182 serum samples from 11 American states and
3 Canadian provinces were positive for antibodies to RacPyV VP1
when analyzed by ELISA (from a total of 499 samples analyzed).
Numbers of available samples per state ranged from 3 (WA) to 75
(GA), and antibodies to RacPyV were detected in serum samples
from all states and provinces examined (Table 1). Results of the
seroprevalence survey demonstrate that raccoons from 11 states
across the U.S. have antibodies to the VP1 capsid protein of RacPyV
(Fig. 1). The seropositivity in areas where tumors have been
diagnosed (CA and WA) was greater than 60%, and ranged in other
states from 5% in WV to 57% in NY. Percentage of positive samples
from Canada ranged from 43% to 95%. The seroprevalence of rac-
coons in CA was compared to that of raccoons in other states
(Fig. 2). The proportion of seropositive raccoons in CA was sig-
niﬁcantly higher than the proportion in a majority of the states
examined (FL, GA, IL, KY, NJ, WV; Po0.05, Fisher's exact test). The
most striking difference in seropositivity was between raccoons
with and without tumors (Fig. 3). In addition, a signiﬁcant differ-
ence between the seroprevalence of adults and juveniles was
determined (Po0.05, Fisher's exact test). Juvenile raccoons had a
seropositivity of 16.8%, while 45.7% of samples adult raccoons
were seropositive. No signiﬁcant difference was detected between
proportions of seropositive samples from females compared to
males nor of raccoons from rural habitats compared to those from
suburban or urban habitats.
RacPyV antibody titers
RacPyV antibody titer values ranged from 200 to 102,400, and
varied by state (Fig. 4 and Table 1). Highest titer values 1:102400
were detected in samples from CA, GA, and MO. The mean titerTable 1
Serum samples collected from free ranging raccoons in North America and ana-
lyzed for seroreactivity to RacPyV VP1 protein by indirect ELISA.
State or
Province
Number of
samples
Proportion
of Positive
samples
Median titer
value
Range of
titer values
CA 61 0.62 9600 200–102,400
FL 31 0.16 200 200–800
GA 75 0.39 3200 200–102,400
IL 32 0.09 1600 400–25,600
KY 47 0.13 200 200–400
MA 11 0.27 25600 12800–
25,600
MO 34 0.29 400 200–102,400
NJ 62 0.23 3200 200–25,600
NY 28 0.57 400 200–3200
WA 3 0.67 6400 6400–6400
WV 20 0.05 200 200–200
NB 20 0.95 800 200–25,600
ON 40 0.525 6400 200–25,600
QU 35 0.43 6400 200–25,600
total 499 0.36 1600 200–102,400values varied signiﬁcantly between CA and the following states:
FL, NY, KY and the province of NB (Po0.0001, Kruskall–Wallis). In
addition, the mean titer values of serum samples from raccoons
with tumors were signiﬁcantly higher than from without tumors
(P¼0.0065, Mann–Whitney) (Table 2).
RacPyV consensus sequence
The consensus RacPyV sequence derived from the alignment of
17 tumor-derived sequences with whole viral genome coverage
(Rac 2, 3, 4, 5, 8–20) is given in Supplemental FASTA ﬁle. The
sequences obtained from tumor tissue from the fourth (Rac 4) and
17 (Rac 17th) tumor-bearing raccoons matched the consensus
sequence identically. The RacPyV sequences derived from the
remaining California tumor samples exhibit a range of 1–11 single
nucleotide polymorphisms (SNPs) that varied from the consensus
sequence (average¼5.1, standard deviation¼4.1, see Table 3 ). In
addition, seven sequences (Rac 5, 9, 10, 12, 14, 19 20) had deletions
of 1 (Rac 10, 14) to 349 (Rac 9) nucleotides. Sequence identities
ranged from 93.04% (Rac 9) to 99.98% (Rac 2, 3, 11, 14, 18).
The sequence from the tumor identiﬁed in Washington con-
tained 24 SNPs, two of which (base pair (bp) 1503 and 2172) were
unique to that sample and not shared with any other sequence
from any other tumor sequences. Two SNPs in the T antigen (TAg)
coding region at (bp 18 and 2145), and four in the VP1 coding
region (bp 2866, 3223, and 3328) were present in sequences from
seven tumors (Rac 5, 8, 12, 13, 15, 16, and 19). Sequence identity to
the consensus sequence was 99.52%.
In four tumor-bearing raccoons where viral sequences could be
derived from non-tumor tissue, all raccoons exhibited identical
RacPyV sequences between tumor and non-tumor tissue (Cali-
fornia Rac 14, 16, and 17 and Washington Rac 13). The RacPyV
sequence obtained from tonsil tissue from one California raccoon
(Rac 16) did not match the sequence from the tumor tissue from
that animal. The sequence from the tonsil tissue from this raccoon
matched that of the RacPyV consensus sequence.
RacPyV segments sequenced from non-tumor tissue from three
of the six raccoons in California without tumors shared SNPs with
sequences from tumor tissue. In the other three cases, there were
unique SNPs identiﬁed in each sample (1 unique SNP in
2012F20Rac1Mar, 1 unique SNP in 2013D29Rac1CC, and 2 unique
SNPs in 2012E29Rac1Pla), however, none of the SNPs resulted in
an amino acid difference from the consensus.
Across all 23 raccoons examined, the VP1 coding region con-
tained the most SNPs detected (67 SNPs) compared to other cod-
ing regions (TAg: 46 SNPs, VP2: 12 SNPs, NCRR: 2 SNPs). The
numbers of SNPs in distinct areas of the RacPyV genome were not
statistically signiﬁcant as determined by Chi-square analysis.
Amino acid variation between RacPyV sequences
Tumor sequences
Within viral genes, eight (Rac 3, 5, 8, 12, 13, 15, 16, 19) of the
sequences from tumors had SNPs in the TAg region, 10 (Rac 2, 5, 8,
10, 11, 12, 13, 15, 16, 19) had SNPs in the VP1 region, and two (Rac
13 and 20) had SNPs in VP2. Of the SNPs found in the TAg region
two were classiﬁed as point mutations resulting in amino acid
changes in the predicted large T protein (Rac 3 and 13) and one
resulted in amino acid changes in the predicted small T protein
(Rac 13). All 10 SNPs in the VP1 region were synonymous, while
both of the SNPs in the VP2 region were nonsynonymous point
mutations that resulted in changes in amino acid sequences from
the consensus.
In addition to SNPs, sequences from seven tumors (Rac 5, 9, 10,
12, 14, 19, 20) had deletions of one to 25 nucleotides. Two of the
sequences resulted in a 4 amino acid truncation of the LT protein
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Fig. 1. Seroprevalence of antibodies to RacPyV VP1 protein in serum samples from raccoons in the United States. Number of samples in states ranged from 3 (in WA) to 75 (in
GA). Seroprevalence in states with tumors (CA and WA) are greater than 0.6, with other states ranging from 0.05 (in WV) to 0.57 (in NY).
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Fig. 2. Number of positive and negative serum samples from raccoons in 10 states
and three provinces. States with signiﬁcantly lower seroprevalence percentages
than CA are indicated by an asterisk (Po0.05).
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Fig. 3. Proportions of seropositive serum samples from (1) raccoons with and
without tumors, (2) adult and juvenile raccoons, (3) female and male raccoons, and
(4) raccoons from rural and suburban or urban environments. Statistically sig-
niﬁcant differences of seropositive proportions between groups are indicated by
asterisks (Po0.05).
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Fig. 4. Titer values for serum samples from raccoons in the United States and
Canada analyzed by indirect ELISA. Highest titer values (1:102,400) were detected
in samples from CA, GA, and MO. The mean titer values varied signiﬁcantly
between CA and FL, KY, NY, and NB (Po0.0001). Median titers are represented by
the black horizontal bar in each column.
Table 2
Mean titer values of serum samples from raccoons with tumors were signiﬁcantly
higher (P¼0.0065, Mann Whitney) compared to samples from raccoons with
tumors.
Titer values Tumor Non-tumor
Number of values 7 176
Minimum 3200 200
25% Percentile 6400 400
Median 12,800 1600
75% Percentile 25,600 12,800
Maximum 102,400 102,400
Mean 26,971 9930
Std. Deviation 34,359 19,218
Std. Error of Mean 12,986 1449
M.E. Church et al. / Virology 489 (2016) 292–299294(Rac 9) and in an in-frame 4 amino acid deletion (Rac 19) 21 amino
acids from the C terminus of the LT protein. Deletions in the T
antigen region resulted in amino acid changes in predicted small Tprotein amino acid sequences in four tumor sequences. Nucleotide
deletions in Rac 10 and 20 resulted in single amino acid changes in
the sT protein. The sT protein of Rac 12 was truncated by 7 amino
acids at the C terminus, and the sT protein of Rac 5 had an 8 amino
acid deletion mid-protein. Sequences from two tumors (Rac 9, 12)
had deletions in the VP1 gene resulting in a 107 amino acid
Table 3
Summary of sequencing data from (1) tumor samples, (2) non-tumor tissue from raccoons with tumors, and (3) non-tumor tissue from raccoons without tumors. No signiﬁcant differences were detected between sequences from
any of the groups.
Raccoon Tumor State Tissue
sequenced
Regions ampliﬁed Size of
amplicon
No. of SNPs SNP position(s) Deletion
positions
% sequence iden-
tity to consensus
2010D29Rac1Mar (Rac 4) Yes CA Tumor entire RacPyV
genome
5016 Consensus 100.00%
2014D09Rac1Mar (Rac 17) Yes CA Tumor entire RacPyV
genome
5016 Consensus 100.00%
2011F09Rac1Mar (Rac 2) Yes CA Tumor entire RacPyV
genome
5016 1 3295 (VP1) 99.98%
2011H23Rac1Mar (Rac 3) Yes CA Tumor entire RacPyV
genome
5016 1 2696 (TAg) 99.98%
2012F19Rac1Mar (Rac 11) Yes CA Tumor entire RacPyV
genome
5016 1 3358 (VP1) 99.98%
2014G29Rac1Mar (Rac 18) Yes CA Tumor entire RacPyV
genome
5016 1 4279 (VP2) 99.98%
2013F12Rac1Mar (Rac 14) Yes CA Tumor entire RacPyV
genome
5015 single nucleotide deletion 4564 (VP2) 99.98%
2015C27Rac1Mar (Rac 20) Yes CA Tumor entire RacPyV
genome
4991 1 (1 deletion) 4252 (VP2) 290-314 (TAg) 99.48%
2012D18Rac1Son (Rac 9) Yes CA Tumor entire RacPyV
genome
4718 2 deletions 2692 -2742 (TAg-
VP1), 2744 -3041
(VP1)
93.04%
2012E04Rac1Mar (Rac 10) Yes CA Tumor entire RacPyV
genome
5015 1 (1 deletion) 3160 (VP1), 4843 (NCRR) 385 (TAg) 99.94%
2012K15Rac1Yolo (Rac 12) Yes CA Tumor entire RacPyV
genome
4945 7 (2 deletions) 18 (TAg), 2145 (TAg), 2776 (VP1), 2866 (VP1), 3058
(VP1), 3223 (VP1), 3328 (VP1)
523 - 545 (TAg),
3640 -3687 (VP1)
98.44%
2012C07Rac1CC (Rac 8) Yes CA Tumor entire RacPyV
genome
5016 8 18 (TAg), 2145 (TAg), 2776 (VP1), 2866 (VP1), 3058
(VP1), 3223 (VP1), 3328 (VP1), 3640 (VP1)
99.84%
2013G02Rac1Mar (Rac 15) Yes CA Tumor entire RacPyV
genome
5016 9 18 (TAg), 1401 (TAg), 1665 (TAg), 2145 (TAg), 2866
(VP1), 3058 (VP1), 3223 (VP1), 3346 (VP1), 3640
(VP1)
99.82%
2013I26Rac1Mar (Rac 16) Yes CA Tumor entire RacPyV
genome
5016 9 18 (TAg), 1401 (TAg), 1665 (TAg), 2145 (TAg), 2866
(VP1), 3058 (VP1), 3223 (VP1), 3346 (VP1), 3640
(VP1)
99.82%
2011L28Rac1SF (Rac 5) Yes CA Tumor entire RacPyV
genome
4978 9 (2 deletions) 18 (TAg), 1401 (TAg), 1665 (TAg), 2145 (TAg), 2866
(VP1), 3058 (VP1), 3223 (VP1), 3346 (VP1), 3640
(VP1)
250 - 275 (TAg),
4781 - 4792
(NCRR)
99.06%
2014H22Rac1Pla (Rac 19) Yes CA Tumor entire RacPyV
genome
5004 11 (1 deletion) 18 (TAg), 1401 (TAg), 1665 (TAg), 2145 (TAg), 2328
(TAg), 2696 (TAg), 2866 (VP1), 3058 (VP1), 3223
(VP1), 3640 (VP1), 4886 (NCRR)
2668-2679 (TAg) 99.54%
2013A08Rac1SnoWA (Rac
13)
Yes WA Tumor entire RacPyV
genome
5016 24 18 (TAg), 51 (TAg), 306 (TAg), 382 (TAg), 1503
(TAg), 2145 (TAg), 2160 (TAg), 2172 (TAg), 2214
(TAg), 2586 (TAg), 2974 (VP1), 3058 (VP1), 3172
(VP1), 3208 (VP1), 3505 (VP1), 3535 (VP1), 3568
(VP1), 3592 (VP1), 3730 (VP1), 4009 (VP2), 4019
(VP2), 4283 (VP2), 4828 (VP2), 4955 (VP2)
99.52%
2013A08Rac1WA (Rac 13) Yes WA OPN swab entire RacPyV
genome
5016 no variation from sequence
determined from tumor
from same raccoon
99.52%
2013F12Rac1Mar (Rac 14) Yes CA Tonsil TAg: bp 1002-1676
VP: bp 2962-4209
1923 no variation from sequence
determined from tumor
from same raccoon
ND
2013I26Rac1Mar (Rac 16) Yes CA Tonsil TAg: bp 1002-1674
VP: bp 2509-4209
2374 1 1665 (TAg) ND
2014D09Rac1Mar (Rac 17) Yes CA Spleen 2375 ND
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M.E. Church et al. / Virology 489 (2016) 292–299296truncation of the predicted protein (Rac 9) and in in-frame mid-
protein deletion of 16 amino acids (Rac 12). A single nucleotide
deletion in Rac 14 resulted in an amino acid change in VP2 protein.
Non-tumor sequences
Nucleotide sequences obtained from non-tumor tissue in four
raccoons with tumors did not result in any amino acid sequence
variation from the consensus sequence derived from tumor
sequences.
Sequence variation from only one of the six nucleotide
sequences obtained from non-tumor tissues from raccoons was
synonymous. Feces from raccoon 2013D29Rac1CC, had a sequence
that shared many SNPs in the sequence from tumor tissue from
Rac 13, which resulted in two amino acid changes detected in Rac
13 as well: one amino acid change in the sT protein and one amino
acid change in the VP2 protein.Conclusions
Exposure to RacPyV is widespread and not limited to tumor endemic
areas
To assess the geographical seroprevalence of RacPyV, we
developed an indirect ELISA utilizing a recombinant capsid pro-
tein, RacPyV VP1, and analyzed sera from 499 raccoons across
North America. We found that although RacPyV-associated neu-
roglial tumors have only been detected in raccoons in California,
Oregon and Washington, raccoons across North America are
exposed to RacPyV. This is similar to widespread exposure pat-
terns reported for human polyomaviruses (DeCaprio and Garcea,
2013; Kean et al., 2009; Nguyen et al., 2009). Seropositivity per-
centages in raccoons from Canadian provinces were just as high or
higher compared to California, and these data warrant further
investigations into tumor incidence in this region. The ser-
opositivity percentage was signiﬁcantly higher in American wes-
tern states (where tumors have been diagnosed) compared to the
eastern states (where no tumors have been diagnosed). Several
scenarios could explain this discrepancy. First, this could represent
lower exposure to RacPyV in eastern states, coinciding with a
lower/undetected incidence of associated brain tumors in the east.
Second, it is possible that there is a yet-undiscovered poly-
omavirus endemic in raccoons in eastern states with a VP1
sequence that varies from the RacPyV isolates sequenced in the
western US. This could result in a different amino acid sequences,
allowing for cross-reactivity by antibodies and account for the
lower seropositivity and the lower median titer values in the
eastern U.S. compared to samples from the western U.S. We
obtained spleen and kidney samples from raccoons in GA and KY,
respectively, in an attempt to evaluate RacPyV sequences from east
coast raccoons. We were unsuccessful in obtaining interpretable
sequence information, which may be due to several reasons: 1)
none of the samples contained RacPyV, 2) RacPyV was present in
too small a quantity to amplify by directed rolling circle ampliﬁ-
cation, or 3) RacPyV sequence in these tissues varied too much
from the consensus sequence to be detected by directed rolling
circle ampliﬁcation. Future studies to examine RacPyV in these
tissues or additional prospectively collected samples might be
informative utilizing more sensitive techniques like deep
sequencing.
Interestingly, prevalence of seropositive raccoons was highest
in samples from New Brunswick, which is geographically disparate
from where RacPyV associated tumors have been diagnosed. This
discrepancy could be due to a number of reasons. First, there
might be tumors that have previously gone undiagnosed in New
Brunswick. Additionally, signalment was not provided in the data
M.E. Church et al. / Virology 489 (2016) 292–299 297gathered from this location, meaning it is possible that adult
animals were overrepresented compared to California or other
states. Finally, New Brunswick was also the only state or province
with samples collected from 2008. Therefore this could represent a
year of viral introduction or rapid spread through raccoon popu-
lations, however we would need samples from other areas in that
year to conﬁrm this.
Seropositivity is higher in older raccoons compared to young raccoons
Seropositivity is greater in adult raccoons than in young rac-
coons, which is a trend that is also seen in seroprevalence studies
of human polyomaviruses (Kunitake et al., 1995; Lim et al., 2014;
Martel-Jantin et al., 2013; Reploeg et al., 2001). Polyomavirus
infection in humans occurs in childhood, though the exact mode of
transmission is unknown, and for BK virus, has been suggested to
occur vertically as well as horizontally (Boldorini et al., 2010;
Pietropaolo et al., 1998). The mode of transmission of RacPyV is
still unknown, though our ﬁnding that older raccoons are exposed
to RacPyV at a greater percentage than young raccoons suggests it
could be similar to other polyomaviruses. No signiﬁcant differ-
ences in exposure were detected between sexes or between rac-
coons in different habitats (suburban vs. rural), which is similar to
what has been shown in human polyomaviruses (DeCaprio and
Garcea, 2013).
Elevated titers in tumor-affected raccoons
Antibody titers are higher in raccoons with tumors and in
raccoons in tumor endemic areas. Elevated antibody titers asso-
ciated with polyomavirus induced disease have been reported in
studies of progressive multifocal leukoencephalopathy caused by
JC virus (Tan and Koralnik, 2010; Weber et al., 2001) and Merkel
cell carcinoma caused by Merkel cell polyomavirus (Touze et al.,
2011). This increased humoral response in tumor-affected rac-
coons suggests a prolonged exposure or an increase in viral
replication during development of disease, followed by a humoral
response and further supports previous work demonstrating the
role of RacPyV in causation of these tumors (Brostoff et al., 2014).
RacPyV sequence variation is minor between groups of raccoons
Geographically discrete disease outbreaks, similar to the loca-
lized occurrence of these RacPyV-associated tumors are attributed
to a number of causes, including: a change in the genetic makeup
of the causative pathogen, a unique genomic susceptibility marker
of the host, or a unique co-morbidity (DeCaprio and Garcea, 2013).
Here, we examined RacPyV sequences from tissues of raccoons
with and without tumors and have demonstrated that there is no
compelling genetic variation between RacPyV isolates from these
raccoons (e.g. in tumor versus non-tumor tissue). In addition, full
necropsies were performed on all raccoons with tumors and no
concurrent infections were diagnosed at the time of death by gross
or histological examination. Thus, while previous infection or
unidentiﬁed co-morbid conditions might have predisposed rac-
coons to tumor formation, no such conditions were identiﬁed at
the time of necropsy in this investigation. However, we cannot
rule out any contributory effect of the immune status of the
affected animals at the time that they were infected with RacPyV.
Another important possibility is that there is something inherent
to the raccoon genome within the western United States (i.e. MHC
haplotype) that contributes to tumor formation following RacPyV
infection. Further investigation into the genetic identity of rac-
coons from disparate geographic locations might elucidate a
genetic predisposition to viral associated transformation. This
work suggests that RacPyV-associated disease is more complexthan the variation in viral sequence (either by integration or
mutation) seen with other polyomaviruses (i.e. JC virus (Gosert et
al., 2010; Loeber and Dorries, 1988) and mouse polyomavirus
(Ramqvist and Dalianis, 2009)) and may involve a complex inter-
play between environment and co-pathogens. RacPyV might
represent a newly emergent infection in raccoons in the western
US, and by continuing to study the genomic drift, we will be able
to identify speciﬁc changes that are unique to, or necessary for
disease causation.Materials and methods
Serum collection
Serum samples were collected from 499 raccoons from 11
United States (CA, FL, GA, IL, KY, MA, MO, NJ, NY, WA, WV) and
three Canadian provinces (NB, ON, QU). Samples were collected for
either routine disease surveillance or part of unrelated investiga-
tions. Some samples were aliquots from blood taken for clinical
evaluation at rehabilitation centers (CA, IL, MA, WA), while others
were collected as part of infectious disease surveillance projects
(CA, FL, GA, KY, MO, NJ, NY, WV, BN, ON, QU) including those
monitoring rabies, canine distemper virus, and Leptospira spp. All
samples were collected in accordance with the speciﬁc animal care
and control guidelines established at each institution. Serum
samples were initially stored at collaborator institutions at 4 °C (up
to 3 months). Samples were either shipped directly within that
time period, or stored at 20° or 80 °C until shipment. Samples
were shipped on dry ice, and stored at 80 °C at UC Davis until
time of analysis.ELISA
RacPyV-speciﬁc immunoglobulin (IgG) was detected utilizing
an indirect ELISA. 96-well Maxisorp plates (Fisher Scientiﬁc) were
coated with recombinant RacPyV VP1 antigen, produced using a
baculovirus expression system in insect cells (Church et al., sub-
mitted for publication). Brieﬂy, 10 ng puriﬁed recombinant RacPyV
VP1 antigen per well was diluted in PBS and stored at 4 °C over-
night and/or for up to 4 weeks prior to use. Plates were washed in
PBS with 0.1% Tween 20 (PBS-T) and blocked with 5% nonfat milk
in PBS-T for two hours at room temperature. Serum samples were
diluted 1:200 in 5% milk PBS-T and incubated for two hours at
room temperature. Plates were washed in PBS-T and then incu-
bated for one hour at room temperature with either mouse-anti-
rabbit secondary antibodies (control; Bio-Rac, Hercules, CA, USA)
or goat-anti-raccoon secondary antibodies conjugated to horse-
radish peroxidase (Bethyl Laboratories, Montgomery, TX, USA).
ELISA plates were then washed in PBS-T and secondary IgG bind-
ing was visualized by addition of 100 μL of 2, 20-Azino-di(3-
ethylbenzthiazoline-6-sulfonate) (ABTS) HRP substrate solution
while shaking (KPL Inc., Gaithersburg, MD, USA). Optical density
(OD) was measured at 405 nm on a BioTek ELx808 absorbance
microplate reader. Each plate contained a column with a positive
control antibody (rabbit anti-VP1 polyclonal antibody) and a
negative control antibody (pre-immune rabbit serum). For each
sample, the corrected OD was calculated by subtracting the
negative control antibody from the OD of the sample well for each
serum sample. The cut-off value (CO) was calculated as follows:
CO¼Aþ2SD, where A is the average OD of all dilutions of negative
control antibody on the plate and SD is the standard deviation.
Samples were considered positive when the corrected OD was
above the cut-off, and titers were deﬁned as the highest dilution
past the cut-off.
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Tumor tissue was collected from 16 raccoons in CA and 1 from
WA for sequencing of the RacPyV genome. Persistent PyVs have
been detected in many different tissues, including kidney, spleen,
tonsil, oral cavity, skin, and gastrointestinal tract, (Laude et al.,
2010; Chesters et al., 1983; Dubensky and Villarreal, 1984; Sadeghi
et al., 2014; Toracchio et al., 2010) therefore a variety of non-tumor
tissues were sampled for DNA extraction. Biological samples
(oropharyngeal/nasal swabs, tonsil, and spleen) from a subset of
these tumor-bearing raccoons (3 from CA and 1 from WA) were
also collected. Biological samples (urine, oropharyngeal/nasal
swabs, feces, skin, and olfactory bulb) from 6 raccoons in California
that did not have tumors were collected as well. All samples were
donated fromwildlife rehabilitators in Washington (PAWSWildlife
Center in Snowach County) and from California including Wild-
Care in Marin County, Lindsay Wildlife Museum in Contra Costa
County, Sonoma County Wildlife Rescue, Grass Valley Wildlife
Rehabilitation & Release and USDA APHIS Wildlife Services in
Sacramento County. Spleen samples were collected from 32 rac-
coons in Georgia and kidney samples from 14 raccoons in Ken-
tucky from the Southeastern Cooperative Wildlife Disease Study.
Tissue samples were maintained at 80 °C until DNA extraction.
DNA from tumor tissue samples was extracted using Qiagen
DNeasy Blood and Tissue kit following the manufacturer's
instructions. Tissue samples from non-tumor samples were
thawed in a chaotropic lysis buffer (DXB, Qiagen, Valencia, CA) and
immediately homogenized in a GenoGrinder2000 (SpexCertiprep,
Metuchen, NJ) for 2 min at 1000 strokes per minute. Homogenized
tissue pieces were proteinase K digested at 56° C overnight. Total
nucleic acids (including gDNA and RNA) were extracted from
lysates with adapted standardized protocols as previously descri-
bed (Mapes et al., 2008). Brieﬂy, lysates were extracted on
Whatman ﬁlters in a Corbett X-Tractor platform (Qiagen, Valencia,
CA). Nucleic acids were eluted into 150 mL of PCR-grade nuclease-
free water (Fisher) and 5 ml ampliﬁed in subsequent PCR reactions.
Extracted DNA from non-tumor samples were enriched for
circular DNA using directed rolling circular ampliﬁcation following
a protocol outlined by Rockett et al. (2015) using Phi29 DNA
polymerase. Circular template was initially primed with a primer
set targeting the VP1 gene and modiﬁed with phosphorothioate on
the two terminal 30 bases to protect against phi29 single strand
exonuclease activity. Primers (0.4 μM) and 2 μL template were
combined with 1 phi29 buffer (Thermo Scientiﬁc, Scoresby,
Australia) and water up to 10 mL at 95 °C for 3 min. The template
was then ampliﬁed using 0.4 mM primer, 1 phi29 buffer, 2 ng/μL
bovine serum albumin, 15 mM dNTPs, 2 U/μL phi29 DNA poly-
merase (Thermo Scientiﬁc, Scoresby, Australia), and water to a
ﬁnal reaction volume of 10 μL. This was combined with the pre-
ampliﬁcation mix and incubated at 30 °C for 24 h, followed by
phi29 inactivation at 65 °C for 10 min and cooling to 4 °C.
Sequencing
Standard PCR with Accuprime DNA Taq polymerase (Life
Technologies, Thermo Fisher Scientiﬁc) was then performed to
amplify the RacPyV genome from the product of the dRCA reac-
tions for sequencing. Samples were sequenced by at the College of
Biological Sciences UCDNA Sequencing Facility Core Facility using
Sanger sequencing protocols (BigDye
s
Terminator vs. 3.1 Cycle
Sequencing Kit). Sequence reads were assembled using MacVector
(Macvector, Inc.) and VectorNTI (Life Technologies) software. A
consensus sequence for RacPyV sequences from tumor samples
was obtained using the following criteria: if all or all but one
sample agree, the consensus was deﬁned by the sequence con-
tribution and any unconﬁrmed position will be designated N. Thistumor consensus sequence was then compared to the segments of
RacPyV sequenced from non-tumor tissues from raccoons in
California and Washington with and without tumors, and from the
spleens of raccoons from Georgia.
Statistical analysis
R statistical software was used to perform statistical analyses
(signiﬁcance level set at 5%) and to create maps and graphs.
Comparisons between seroprevalence rates between different
groups of raccoons (sex, age, geography, ecosystem type) were
made using Fisher’s exact test. In order to compare antibody titers
between groups, a one-way ANOVA was applied using GraphPad
Prism software. P values less than 0.05 were considered
signiﬁcant.
Statistical analysis to determine the signiﬁcance of the
nucleotide differences between RacPyV sequences was performed
using an exact test of goodness of ﬁt (using number of single
nucleotide polymorphisms) and a Fisher’s exact test (using per-
centage of nucleotide differences from the tumor consensus
sequence). Sequence variation was compared between the fol-
lowing cohorts: 1) tumor tissue 2) non-tumor tissue from tumor-
bearing raccoons 3) non-tumor tissue from non-tumor bearing
raccoons in California, and 4) non-tumor tissue from non-tumor
bearing raccoons in Georgia.Acknowledgments
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